With regard to the efficacy of ALKi for CNS metastasis in pts with ALK rearrangement-positive NSCLC, much evidence was reported at the ASCO Annual Meeting in 2015 (Table 1), and in this section, we review this evidence in detail. The gene discussed is ALK; the disease is non-small cell lung carcinoma.